Table 1.

Basic characteristics of 23 patients with primary hepatobiliary mucoepidermoid carcinoma, including in the liver, gallbladder and biliary tract, reported in the literature

Case	Year	Area	Age (year)	Gender	Location	Metastasis	Size (cm)	Hepatitis	AFP ng/ml	CA199 u/ml	CEA ng/ml	Treatment	OS (day)	Reference
1	1971	Argentina	44	M	RL	Non	15	Np	Np	Np	Np	S	45
2	1980	Hong Kong	65	M	RL	Y	8	Np	Np	Np	Np	Con	14
3		Hong Kong	63	F	LL	Y	6	Np	Np	Np	Np	Con	16
4	1982	Hong Kong	44	F	LL	Non	12	HBV	Np	Np	Np	S + C	180	49
5		Hong Kong	66	M	BD	Y	4	Non	Np	Np	Np	PTCD+S	7
6		Hong Kong	62	M	BD	Non	1.5	Non	Np	Np	Np	S	300+
7	1984	Japan	78	M	LL	Y	11	Np	12.5	Np	1300	C	90	42
8	1986	Krean	35	M	LL	Non	18	Np	< 5	Np	Np	Con	14
9	1986	Australia	59	F	RL	Y	18	Np	Np	Np	Np	S	14
10	1987	Japan	46	F	LL	Non	3	Np	20	Np	Np	S	330	30
11	1992	Italy	66	F	LL	Y	9.5	Non	< 5	500	< 2	S	180	41
12	1994	Krean	68	M	LL	Non	10	Np	Np	Np	Np	TACE+C	1095
13	2000	Thailand	64	M	LL	Y	5	Np	Np	Np	Np	Con	210
14	2003	Krean	52	M	LL	Y	7	Np	< 5	400	Np	S	180	28
15	2004	Krean	69	F	RL	Y	16	Non	< 5	240	Np	S	120
16	2008	Japan	81	F	RL	Y	10	Non	< 5	14,893	Np	C	117
17	2011	Krean	70	M	BD	Y	8	HCV	< 5	349	Np	R + C	106
18	2012	Japan	68	M	BD	Y	5	Non	Np	50.8	Np	S + R + C	90+	29
19	2013	America	83	F	BD	Y	2	Np	Np	940	10	S + C	390	7
20	2014	China (mainland)	60	F	LL	Y	8.5	Non	< 5	50	Np	S + R	180
21	2019	India	50	M	GB	Y	8	Non	< 5	652	77	S	180	1
22	2019	Japan	79	F	RL	Y	4	Non	< 5	415	146	S + R + C	3650+	6
23	2020	China (mainland)	60	M	LL	Non	13	Non	< 5	151	10	S	90	present

Abbreviations: Non Not have, Np Not provided, RL Right liver, LL Left liver, BD Bile duct, GB Gallbladder, HCC Hepatocellular carcinoma, CC Cholangiocarcinoma, ASC Adenosquamous carcinoma, GBC Gallbladder carcinoma, S Surgery, R: Radiotherapy, C Chemotherapy, Con Conservative, TACE Transcatheter arterial chemoembolization, PTCD Percutaneous transhepatic cholangial drainage, OS Overall survival